Ovid Therapeutics Inc (OVID) Stock Price, Quote & News

Company Profile

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 661 7661

Fax: 646 661 4027

Website: www.ovidrx.com

Address:

441 Ninth Avenue, 14th Floor, New York, United States

Love_To_Learn Jun. 16 at 5:51 PM

$CREG bringing u in to beloved $PSTV will need to use $OVID temo 0.29 wormhole activation

0 · Reply

diodor Jun. 16 at 3:59 PM

$OVID Just bought 40k shares.

0 · Reply

PrinceTheGreat Jun. 13 at 8:51 PM

$OVID is this stock Dog shit?

1 · Reply

EsotericDark Jun. 12 at 9:21 PM

$OVID Purchased 5k Shares today. Only position that I'm in the red in right now, but the Insitutional Investment and future prospects make me feel comfortable about moving ahead with this.

0 · Reply

stu_gats Jun. 12 at 5:57 PM

$OVID squeeze?

0 · Reply

scampi90 Jun. 11 at 7:24 PM

$OVID grabbed almost 20k today, so cheap. Looking forward to some positive updates on OV239

1 · Reply

Love_To_Learn Jun. 11 at 6:06 PM

$OVID your 0.32* trying to take the nuwe pop from years ago as 1 of multiple vying for the pop

0 · Reply

Love_To_Learn Jun. 11 at 5:50 PM

$FOXO $OVID overlap ovid had 0.21 active now swapping on and off alot going on market wise guys

0 · Reply

perchedcats Jun. 10 at 2:25 PM

$OVID added more today! expect this to make a big move sometime soon, and looking forward to the june 12 KOL event… unreal that in spite of recent biotech rally this is still around $.33 a share—a great opportunity—and i’ve accumulated as many shares as possible

0 · Reply

Big_Zack22 Jun. 9 at 12:13 PM

$OVID

0 · Reply

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Mar 11, 2025, 8:00 AM EDT - 3 months ago

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 3 months ago

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

Feb 27, 2025, 8:00 AM EST - 3 months ago

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 5, 2025, 8:00 AM EST - 4 months ago

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Sep 11, 2024, 8:00 AM EDT - 9 months ago

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

Aug 19, 2024, 11:00 AM EDT - 10 months ago

Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm

Aug 18, 2024, 11:00 AM EDT - 10 months ago

Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm

Aug 17, 2024, 11:00 AM EDT - 10 months ago

Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 10 months ago

Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm

Aug 15, 2024, 11:00 AM EDT - 10 months ago

Ovid Therapeutics Inc Shareholders Encouraged To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 10:30 PM EDT - 10 months ago

Ovid Therapeutics Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 1:15 AM EDT - 10 months ago

Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

Aug 13, 2024, 8:00 AM EDT - 10 months ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

Aug 12, 2024, 11:55 PM EDT - 10 months ago

Ovid Therapeutics Inc Investors Invited To Join Fraud Investigation With Schall Law Firm

Aug 9, 2024, 9:15 PM EDT - 11 months ago

Investors Of Ovid Therapeutics Inc Can Participate In Fraud Investigation With The Schall Law Firm

Aug 8, 2024, 4:00 PM EDT - 11 months ago

Investors Of Ovid Therapeutics Inc Eligible To Join Fraud Investigation With The Schall Law Firm

Aug 7, 2024, 11:30 PM EDT - 11 months ago

Investors Of Ovid Therapeutics Inc Can Join Fraud Investigation With The Schall Law Firm

Aug 6, 2024, 4:00 PM EDT - 11 months ago

Ovid Therapeutics Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm

Aug 2, 2024, 10:00 AM EDT - 11 months ago

OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Jul 30, 2024, 8:00 AM EDT - 11 months ago

Ovid Therapeutics to Present at Upcoming August Investor Conferences

Jul 23, 2024, 8:00 AM EDT - 11 months ago

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Jul 1, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations

Jun 17, 2024, 8:58 AM EDT - 1 year ago

What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?

TAK

Jun 17, 2024, 6:55 AM EDT - 1 year ago

Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat

May 14, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

May 13, 2024, 7:00 AM EDT - 1 year ago

Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Apr 9, 2024, 10:48 AM EDT - 1 year ago

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

Apr 4, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 8, 2024, 8:00 AM EST - 1 year ago

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Feb 28, 2024, 8:00 AM EST - 1 year ago

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Feb 6, 2024, 8:00 AM EST - 1 year ago

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Dec 1, 2023, 7:30 AM EST - 1 year ago

Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)

Nov 3, 2023, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates

Oct 18, 2023, 8:00 AM EDT - 1 year ago

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026

Oct 10, 2023, 8:00 AM EDT - 1 year ago

Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit

Sep 26, 2023, 7:30 AM EDT - 1 year ago

Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023

Sep 20, 2023, 7:30 AM EDT - 1 year ago

Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

Aug 30, 2023, 8:00 AM EDT - 1 year ago

Ovid Therapeutics to Participate in Upcoming September Investor Conferences

Aug 4, 2023, 8:00 AM EDT - 2 years ago

Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023

Jun 28, 2023, 8:00 AM EDT - 2 years ago

Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Ovid Therapeutics Added to Russell 3000® Index

Jun 13, 2023, 2:12 AM EDT - 2 years ago

Ovid Therapeutics: Bullish Outlook Strengthened By Positive 2-Year Open-Label Trial Results

May 5, 2023, 7:30 AM EDT - 2 years ago

Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates

Love_To_Learn Jun. 16 at 5:51 PM

$CREG bringing u in to beloved $PSTV will need to use $OVID temo 0.29 wormhole activation

0 · Reply

diodor Jun. 16 at 3:59 PM

$OVID Just bought 40k shares.

0 · Reply

PrinceTheGreat Jun. 13 at 8:51 PM

$OVID is this stock Dog shit?

1 · Reply

EsotericDark Jun. 12 at 9:21 PM

$OVID Purchased 5k Shares today. Only position that I'm in the red in right now, but the Insitutional Investment and future prospects make me feel comfortable about moving ahead with this.

0 · Reply

stu_gats Jun. 12 at 5:57 PM

$OVID squeeze?

0 · Reply

scampi90 Jun. 11 at 7:24 PM

$OVID grabbed almost 20k today, so cheap. Looking forward to some positive updates on OV239

1 · Reply

Love_To_Learn Jun. 11 at 6:06 PM

$OVID your 0.32* trying to take the nuwe pop from years ago as 1 of multiple vying for the pop

0 · Reply

Love_To_Learn Jun. 11 at 5:50 PM

$FOXO $OVID overlap ovid had 0.21 active now swapping on and off alot going on market wise guys

0 · Reply

perchedcats Jun. 10 at 2:25 PM

0 · Reply

Big_Zack22 Jun. 9 at 12:13 PM

$OVID

0 · Reply

Jtlo Jun. 7 at 11:08 PM

$SPY $OVID $VOR $XBI

0 · Reply

Big_Zack22 Jun. 6 at 1:04 PM

$OVID We will start to see some move here next week

0 · Reply

Love_To_Learn Jun. 5 at 10:58 AM

$AYRO $OVID need your services and help soon

0 · Reply

Jtlo Jun. 4 at 5:18 PM

$OVID push .31

0 · Reply

Jtlo Jun. 3 at 2:38 PM

$OVID lets get to .40

0 · Reply

OLDjimmy2shoes Jun. 2 at 11:53 AM

$OVID here to observe. BioTechs usually have whacky analyst targets, but I like the fact that they have a lot of cash.

1 · Reply

Jtlo May. 29 at 8:40 PM

$OVID can we finally make a run? Too long consolidating in the high .20s

0 · Reply

JarvisFlow May. 27 at 11:30 AM

HC Wainwright & Co. has updated their rating for Ovid Therapeutics ( $OVID ) to Buy with a price target of 1.5.

0 · Reply

Love_To_Learn May. 23 at 7:27 PM

$AYRO $OVID $INUV making changes b4 close

1 · Reply

Jtlo May. 21 at 11:06 PM

$OVID Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025 Ovid’s first program in its KCC2 direct activator library, OV350, has been dosed in a Phase 1 study in Q1 2025; safety and tolerability results expected before year-end Cash, cash equivalents and marketable securities of $43.0 million as of March 31, 2025 are expected to support currently planned operations and development programs into the 2H of 2026 “We’re off to a strong start across our pipeline and programs in what will be a defining year for Ovid,” said Dr. Jeremy Levin, D.Phil., MB BChir., Chairman and CEO of Ovid Therapeutics. “Our lead program, OV329, continues to show promise as a potential next-generation medicine for treatment resistant seizures, and we are on track to share key safety and biomarker data later this year.

1 · Reply

Jtlo May. 21 at 12:29 AM

$OVID can we start flirting with .40s?

1 · Reply

Jtlo May. 19 at 10:42 PM

$OVID no 70+ percent What does that mean?

0 · Reply

Market Cap	19.93M
Revenue (ttm)	570,000.00
Net Income (ttm)	-26.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,636.84%
Debt to Equity Ratio	0.00

Volume	1,254,200
Avg Vol	579,756
Day's Range	N/A - N/A
Shares Out	71.11M
Stochastic %K	11%
Beta	0.08
Analysts	Strong Sell
Price Target	$3.10